A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Single Ascending Dose Study to Asses the Safety, Tolerability, Pharmacokinetics of AZD1446 Including an Open Food Effect Panel in Healthy Male and Non-Fertile Female Volunteers.
Phase of Trial: Phase I
Latest Information Update: 18 Jan 2010
At a glance
- Drugs AZD 1446 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms SAD
- Sponsors AstraZeneca
- 09 Dec 2009 Additional trial acronym (SAD) identified as reported by ClinicalTrials.gov.
- 09 Dec 2009 Actual end date (Apr 2009) added as reported by ClinicalTrials.gov.
- 16 May 2009 Actual patient number (110) added as reported by ClinicalTrials.gov.